Sarepta Therapeutics Inc Stock Price, News & Analysis

Sarepta Therapeutics (NASDAQ:SRPT) reported preliminary Q3 2021 financial results, projecting net product revenues of approximately $166.9 million, a significant increase from $121.4 million in Q3 2020. As of September 30, 2021, the company reported $1.6 billion in cash and investments, down from $1.9 billion at the end of 2020. The results are preliminary, and actual results may vary as they have not yet been finalized or reviewed by independent auditors.

Sarepta Therapeutics (Nasdaq: SRPT) announced a public offering of $500 million in common stock, with an additional $75 million option for underwriters. The proceeds will finance clinical trials, commercialization, and business development, including potential acquisitions. Goldman Sachs, J.P. Morgan, Morgan Stanley, and Credit Suisse are the underwriters. The offering is conducted under an effective shelf registration statement filed with the SEC. A preliminary prospectus will detail the terms.

Sarepta Therapeutics (NASDAQ:SRPT) presented new data from its SRP-9001 program for treating Duchenne muscular dystrophy at 'Micro-dystrophin Day'. Key findings include significant improvements in the North Star Ambulatory Assessment (NSAA) scores: an 8.6-point increase in 4-7 year-olds (Study 101), a 2.9-point increase in 6-7 year-olds (Study 102), and a 3.0-point improvement at six months (Study 103). The EMBARK trial, a pivotal Phase 3 study, aims to enroll 120 patients globally. The safety profile remains consistent, with transient treatment-related adverse events. Sarepta emphasizes the urgency in addressing this degenerative disease.

Sarepta Therapeutics (NASDAQ:SRPT) celebrated the grand opening of its 85,000 square foot Genetic Therapies Center of Excellence in Columbus, Ohio, on October 4, 2021. This facility expands their research capabilities and aims to support their pipeline of genetic medicines, including RNA, gene therapy, and gene editing programs. With 70 employees currently, Sarepta plans to double its workforce by the end of 2022. The center will also enhance collaboration with local partners and bolster Ohio's position in biotechnology.

Sarepta Therapeutics (NASDAQ:SRPT) has announced the initiation of study SRP-9001-301, also known as EMBARK, in collaboration with Roche. This pivotal study aims to evaluate SRP-9001, a gene transfer therapy for Duchenne muscular dystrophy (DMD). The EMBARK study will take place in the US, Europe, and Asia, marking the first pivotal double-blind gene therapy trial for DMD. The SRP-9001 Micro-dystrophin R&D Day is scheduled for October 11, 2021, to present more details about the trial.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 43 newly hired employees on September 30, 2021, under its 2014 Employment Commencement Incentive Plan. The total awards include options for 48,350 shares and 24,900 restricted stock units (RSUs), with an exercise price of $92.48 per share. Vesting for options occurs monthly over four years, while RSUs vest annually, both contingent on continued employment. This initiative aims to enhance employee retention and performance within the precision genetic medicine sector.

Sarepta Therapeutics (NASDAQ:SRPT) announced plans to initiate Part B of the MOMENTUM study for SRP-5051, potentially a pivotal trial following positive FDA interactions. This study aims to treat Duchenne muscular dystrophy and will enroll 20-40 patients aged 7 to 21, including both ambulatory and non-ambulatory individuals. Initial results from Part A show SRP-5051's efficacy, boasting significantly higher dystrophin production compared to existing treatments. The protocol for Part B will emphasize safety with magnesium supplementation due to previously noted reversible hypomagnesemia.

Sarepta Therapeutics (NASDAQ:SRPT) will present at the World Muscle Society 2021 Virtual Congress from Sept. 20-24, showcasing its commitment to developing precision genetic medicine for rare diseases. The presentations will cover important data from the company’s gene therapy and RNA platforms and address the prevalence of pre-existing antibodies to the AAVrh74 vector. All presentations will be available on-demand starting Sept. 20, 2021. Sarepta currently leads in therapies for Duchenne muscular dystrophy and has over 40 programs in various development stages.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine, announced participation in two upcoming virtual investor conferences. The events include the Morgan Stanley Global Healthcare Conference on Sept. 13, 2021, at 1:15 p.m. E.T., and the Cantor Fitzgerald Virtual Global Healthcare Conference on Sept. 27, 2021, at 1:20 p.m. E.T. Live webcasts will be available on Sarepta's website, and the presentations will be archived for 90 days. The company is committed to developing therapies for rare diseases, focusing on Duchenne muscular dystrophy and limb-girdle muscular dystrophies.